TG Therapeutics (TGTX) Reports Q4 Loss of $0.37/Share

TG Therapeutics (NASDAQ: TGTX) reported Q4 EPS of ($0.37), versus ($0.48) reported last year. Revenue for the quarter came in at $38.1 million, versus $38.1 million reported last year.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
• GameStop posts higher income despite revenue drop in Q2 2026
• MapLight Therapeutics (MPLT) PT Lowered to $43 at Needham